ReviewLeukemia2012
Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma.
Review in Leukemia, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials.Journal of immunology research · 2018Pooled it
- Review
- Article
- Immunotherapy in Multiple Myeloma.Cells · 2020Review
- A novel approach to remove interference of therapeutic monoclonal antibody with serum protein electrophoresis.Clinical biochemistry · 2020Article
- Inflammation induced PD-L1-specific T cells.Cell stress · 2019Article
- SLAMF6 in health and disease: Implications for therapeutic targeting.Clinical immunology (Orlando, Fla.) · 2019Review
- The T-win® technology: immune-modulating vaccines.Seminars in immunopathology · 2019Review
- Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome byClinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
- A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma.Cancer immunology research · 2018Article
- CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.Frontiers in immunology · 2018Review
- Article
- A novel Fc-engineered human ICAM-1/CD54 antibody with potent anti-myeloma activity developed by cellular panning of phage display libraries.Oncotarget · 2017Article
- Anti-regulatory T cells.Seminars in immunopathology · 2017Review
- Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting.Oncotarget · 2017Review
- Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab.Therapeutic advances in hematology · 2016Review
- Development of Novel Immunotherapies for Multiple Myeloma.International journal of molecular sciences · 2016Review
- PD-L1-specific T cells.Cancer immunology, immunotherapy : CII · 2016Review
- Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.Immunological reviews · 2016Review
- Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date.OncoTargets and therapy · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The introduction of autologous stem cell transplantation combined with the introduction of immunomodulatory drugs (IMiDs) and proteasome inhibitors has significantly improved survival of multiple myeloma patients. However, ultimately the majority of patients will develop refractory disease, indicating the need for new treatment modalities. In preclinical and clinical studies, promising results have been obtained with several monoclonal antibodies (mAbs) targeting the myeloma tumor cell or the bone marrow microenvironment. The mechanisms underlying the therapeutic efficacy of these mAbs include direct induction of tumor cell apoptosis via inhibition or activation of target molecules, complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC). The capability of IMiDs to enhance ADCC and the modulation of various important signaling cascades in myeloma cells by both bortezomib and IMiDs forms the rationale to combine these novel agents with mAbs as new treatment strategies for myeloma patients. In this review, we will give an overview of various mAbs directly targeting myeloma tumor cells or indirectly via effects on the bone marrow microenvironment. Special focus will be on the combination of these mAbs with IMiDs or bortezomib.
Indexed as
Identifiers
21852787What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.